Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ NHF Membership
+ Go to my NHF
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas R�pidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
 What are Bleeding Disorders?
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
-Resources
 Web Links
 Glossary

 

 

 
 

FDA Approved Drugs » 1997
Medical Areas: Hematology | Oncology

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Neumega

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Genetics Institute
Approval Status: Approved November 1997
Treatment Area: platelet deficiency

General Information

Neumega (Oprelvekin) has been approved to promote the production of the body's supply of platelets in cancer patients with solid tumors or lymphoma who are undergoing chemotherapy. By significantly reducing the incidence of severely low platelet levels (thrombocytopenia), a serious side effect which often delays chemotherapy administration, Neumega may give some cancer patients a better chance of receiving the treatment they need to fight their disease.

Clinical Results

In clinical trial involving 170 patients, Neumega reduced the incidence of severe chemotherapy-induced platelet depletion, reduced the need for platelet transfusions, and reduced the number of platelet transfusions required.

Side Effects

The most common adverse effects associated with Neumega treatment included peripheral edema, dyspnea, tachycardia, and conjunctival redness.